November 5, 20218:00 AM - 2:00 PM PT
This course will be a half-day virtual update focusing on key issues for the HIV clinician. If it is safe and practical to meet in person, there will be an in-person component to the course located in San Francisco, California.
Assessment of Needs
Rapid advances in HIV disease management and COVID-19 information require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV, COVID-19, and sexually transmitted infections. Information will be presented through a mix of didactic lectures, clinically relevant cases, and a roundtable discussion developed and led by an expert faculty of HIV/AIDS clinicians and researchers.
After participating in the activity, learners will be better able to:
- Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
- Describe the most current data from recent scientific conferences, including research on new and investigational antiretroviral drugs and approaches
- Describe the potential interaction between COVID-19 and other viruses such as HIV and influenza
- Describe current and investigational therapeutics for the treatment of acute and chronic COVID-19
- Describe the current epidemiology, clinical presentations, and management of the most common sexually transmitted infections (STIs) in adults with HIV infection
Conflicts of Interest
In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.
The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Who Should Attend
This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for patients with HIV infection
- Are currently active in HIV or COVID-19 research
This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.
Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.
Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co., Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at email@example.com or 415-544-9400.